内分支主动脉弓腔内移植物单中心应用经验
单中心回顾性分析2012至2017年54例连续接受内分支主动脉弓腔内修复术(b-TEVAR)的患者,采用定制双内分支移植物(Cook Medical)联合左颈动脉-锁骨下动脉旁路。技术成功53例(98%),30天死亡率和主要卒中发生率均为5.5%(3/54),院内死亡率7.4%(4例)。作者认为b-TEVAR治疗主动脉弓疾病可行且安全,死亡率和卒中率可接受。
要点
- 54例主动脉弓疾病患者接受b-TEVAR,技术成功53例(98%)。
- 30天死亡率和主要卒中发生率均为5.5%(3/54),院内死亡率7.4%(4例)。
- 平均随访12±9个月,发生3例非主动脉相关死亡和1例主动脉相关死亡。
核心结论
- 作者认为,采用b-TEVAR治疗主动脉弓疾病可行且安全,死亡率和卒中率可接受。
研究设计与样本
- 单中心回顾性分析前瞻性收集的连续接受b-TEVAR患者数据,2012年至2017年共54例(38例男性;中位年龄71岁)。
- 所有患者均使用定制双内分支主动脉弓腔内移植物(Cook Medical,Bloomington,Ind)并联合左侧颈动脉-锁骨下动脉旁路。
- 择期腔内修复指征经跨学科病例会议同意。
主要发现
- 适应证包括需弓部修复的退行性主动脉弓或近端降主动脉瘤(n=24)、伴或不伴假腔动脉瘤的夹层(n=26)及穿通性主动脉溃疡(n=4)。
- 43例(80%)为择期手术,11例为紧急手术,包括局限性破裂(n=3)或有症状动脉瘤(n=8),使用已为患者备好的腔内移植物或解剖相似的其他患者移植物。
- 30天死亡率和主要卒中发生率分别为5.5%(3/54)和5.5%(3/54);院内死亡率为7.4%(n=4),次要卒中(包括无症状新发脑部病灶)发生率为5.5%(n=3)。
- 发生2例短暂性脊髓缺血并完全恢复,1例截瘫;未观察到逆行性A型夹层或心脏损伤。
- 3例早期支架移植物相关再干预分别用于纠正近端移植物扭折伴IA型内漏(1例)、桥接支架移植物狭窄(1例)及夹层主动脉上血管持续灌注假腔(1例);平均住院时间为14±8天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Whereas open repair is the "gold standard" for most aortic arch diseases, a subgroup of patients might benefit from an endovascular approach. The introduction of branched stent grafts with dedicated design to address the challenges of the ascending aorta and the aortic arch has opened an entirely new area of treatment for these patients. We investigated the early outcomes of branched thoracic endovascular aortic repair (b-TEVAR) in various types of disease of the aortic arch. METHODS: A retrospective analysis was conducted of prospectively collected data from a single center of all consecutive patients treated with b-TEVAR. The indication for elective endovascular repair was consented in an interdisciplinary case conference. All patients were treated with a custom-made inner branched arch endograft with two internal branches (Cook Medical, Bloomington, Ind) and left-sided carotid-subclavian bypass. Study end points were technical success, 30-day mortality, and complications as well as late complications and reinterventions. RESULTS: Between 2012 and 2017, there were 54 patients (38 male; median age, 71 years) treated with diseases of the aortic arch. Indications for therapy involved degenerative aortic arch or proximal descending aortic aneurysms requiring arch repair (n = 24), dissection with or without false lumen aneurysms (n = 26), and penetrating aortic ulcers (n = 4). Forty-three cases (80%) were performed electively and 11 urgently for contained ruptures (n = 3) or symptomatic aneurysms (n = 8) with endografts already available for the patient or with grafts of other patients with similar anatomy. Technical success was achieved in 53 cases (98%). The 30-day mortality and major stroke incidence were 5.5% (3/54) and 5.5% (3/54), respectively; in-hospital mortality was 7.4% (n = 4), and minor strokes (including asymptomatic new cerebral lesions) occurred in 5.5% (n = 3). There were two cases of transient spinal cord ischemia with complete recovery and one of paraplegia. No retrograde type A dissections or cardiac injuries were observed. Three early stent graft-related reinterventions were necessary to correct proximal endograft kinking with type IA endoleak in one patient, a bridging stent graft stenosis in another patient, and false lumen persistent perfusion from dissected supra-aortic vessels in the last patient. Mean in-hospital stay was 14 ± 8 days. During a mean follow-up of 12 ± 9 months, three nonaorta-related deaths and one aorta-related death distal to the arch repair were observed. CONCLUSIONS: Treatment of aortic arch diseases with b-TEVAR is feasible and safe with acceptable mortality and stroke rates.
引用
- Tsilimparis N, Detter C, Law Y, et al. Single-center experience with an inner branched arch endograft. J Vasc Surg. 2018. PMID: 30477941. doi:10.1016/j.jvs.2018.07.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。